9MW3811 Injection

DRUG4 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Advanced Malignant Solid TumorIdiopathic Pulmonary FibrosisPulmonary FibrosisScarTumor

Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

CompletedNCT05740475

Mabwell (Shanghai) Bioscience Co., Ltd.Pulmonary Fibrosis, Tumor

Start: 2023-03-20End: 2024-01-06Updated: 2025-12-09

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Mabwell (Shanghai) Bioscience Co., Ltd.Idiopathic Pulmonary Fibrosis

Start: 2023-07-26End: 2023-12-31Target: 24Updated: 2023-09-01

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.Advanced Malignant Solid Tumor

Start: 2023-06-30End: 2024-03-31Target: 27Updated: 2023-06-22

Phase 2

A Phase II Study of 9MW3811 in Patients With Pathological Scar

RecruitingNCT07576608

Mabwell (Shanghai) Bioscience Co., Ltd.Scar

Start: 2025-12-29End: 2026-12-01Target: 30Updated: 2026-05-08